HomeNewsBusinessEconomyMarch IIP expands 22.4% over low base, recovery in manufacturing

March IIP expands 22.4% over low base, recovery in manufacturing

Cumulatively, India's industrial output shrunk 8.6 percent in FY21, as compared to a 0.9 percent contraction in FY20. Output shrank during 9 months in 2020-21.

May 12, 2021 / 18:48 IST
Story continues below Advertisement
An employee works inside a small-scale locks manufacturing factory at Aligarh district in Uttar Pradesh. REUTERS/Parivartan Sharma
An employee works inside a small-scale locks manufacturing factory at Aligarh district in Uttar Pradesh. REUTERS/Parivartan Sharma

Industrial output in India expanded due to a low base effect in March, rising 22.4 percent after contracting 3.6 percent in February.

Measured by the Index of Industrial Production (IIP), data for which was released by the Centre on May 12, industrial output had been contracting since January. IIP had contracted by 0.9 percent in January after rising by 1.6 percent in December.

Story continues below Advertisement

"The pace of the IIP's expansion in March 2021 was in the middle of our forecast range (17.5-25.0%). Given the low base of the lockdown, we believe it's more meaningful to compare the industrial performance in March 2021 with March 2019, which reveals a mild albeit sobering contraction of 0.5%," Aditi Nayar, Chief Economist at ICRA, said.

The latest rise in IIP is mainly attributed to the manufacturing sector which saw output increase by 25.8 percent. This comes on an extreme low base, since in March 2020 the country began its cycle of nationwide lockdowns. Back then, manufacturing output had slid by 22.8 percent.

COVID-19 Vaccine
Frequently Asked Questions

View more

How does a vaccine work?

A vaccine works by mimicking a natural infection. A vaccine not only induces immune response to protect people from any future COVID-19 infection, but also helps quickly build herd immunity to put an end to the pandemic. Herd immunity occurs when a sufficient percentage of a population becomes immune to a disease, making the spread of disease from person to person unlikely. The good news is that SARS-CoV-2 virus has been fairly stable, which increases the viability of a vaccine.

How many types of vaccines are there?

There are broadly four types of vaccine — one, a vaccine based on the whole virus (this could be either inactivated, or an attenuated [weakened] virus vaccine); two, a non-replicating viral vector vaccine that uses a benign virus as vector that carries the antigen of SARS-CoV; three, nucleic-acid vaccines that have genetic material like DNA and RNA of antigens like spike protein given to a person, helping human cells decode genetic material and produce the vaccine; and four, protein subunit vaccine wherein the recombinant proteins of SARS-COV-2 along with an adjuvant (booster) is given as a vaccine.

What does it take to develop a vaccine of this kind?

Vaccine development is a long, complex process. Unlike drugs that are given to people with a diseased, vaccines are given to healthy people and also vulnerable sections such as children, pregnant women and the elderly. So rigorous tests are compulsory. History says that the fastest time it took to develop a vaccine is five years, but it usually takes double or sometimes triple that time.
View more
+ Show